EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 3.0

Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C

Tom Ryu, Young Chang, Soung Won Jeong, Jeong-Ju Yoo, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, Seung Up Kim, Jae Young Jang

Clinical and Molecular Hepatology · 2025

DOI: 10.3350/cmh.2024.0904 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Molecular Hepatology, 2025. Verfasst von Tom Ryu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Institute for Digestive Research, Digestive Disease Center, Soonchunhyang University College of Medicine, Seoul, Kor…. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Antiviral Agents, Liver Cirrhosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea, Ministry of Education, Soonchunhyang University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Direct-acting antivirals (DAAs) effectively eradicate hepatitis C virus. This study investigated whether metabolic dysfunction influences the likelihood of fibrosis regression after DAA treatment in patients with chronic hepatitis C (CHC).

Methods

This multicenter, retrospective study included 8,819 patients diagnosed with CHC who were treated with DAAs and achieved a sustained virological response (SVR) between January 2014 and December 2022. Fibrosis regression was defined as a 20% reduction in noninvasive surrogates for liver fibrosis, such as liver stiffness (LS) measured by vibration-controlled transient elastography (VCTE) and the fibrosis-4 (FIB-4) score. Hypercholesterolemia (h-TC) was defined as >200 mg/dL.

Results

The median age of the study population was 59.6 years, with a predominance of male patients (n=4,713, 57.3%). Genotypes 1, 2, and others were confirmed in 3,872 (46.2%), 3,487 (41.6%), and 1,024 (12.2%) patients, respectively. Diabetes mellitus (DM) was present in 1,442 (17.2%) patients and the median LS was 7.50 kPa (interquartile range, 5.30–12.50). Multivariate analysis revealed that the presence of DM and pre-DAA h-TC were independently associated with a decreased probability of fibrosis regression by VCTE. Additionally, pre-DAA h-TC was independently associated with a decreased probability of fibrosis regression by the FIB-4.

Conclusions

Metabolic dysfunction has an unfavorable influence on fibrosis regression in patients with CHC who achieve SVR after DAA treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicAntiviral AgentsLiver CirrhosisHumansMaleMiddle AgedFemaleRetrospective StudiesAgedHepacivirusElasticity Imaging TechniquesSustained Virologic ResponseAdult

Stichwörter der Autor:innen

Diabetes mellitusDirect-acting antiviralsDyslipidemiaLiver fibrosisRegression

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Institute for Digestive Research, Digestive Disease Center, Soonchunhyang University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.
  • Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea.
  • Department of Internal Medicine and Yonsei Liver Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Förderung

  • National Research Foundation of Korea
  • Ministry of Education
  • Soonchunhyang University

Zitieren

APA

Ryu, T., Chang, Y., Jeong, S. W., Yoo, J. J., Lee, S. H., Kim, S. G., Kim, Y. S., Kim, H. S., Kim, S. U., & Jang, J. Y. (2025). Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0904

Vancouver

Ryu T, Chang Y, Jeong SW, Yoo JJ, Lee SH, Kim SG, et al. Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C. Clinical and Molecular Hepatology. 2025. doi:10.3350/cmh.2024.0904

BibTeX
@article{Ryu2025,
  author = {Ryu, Tom and Chang, Young and Jeong, Soung Won and Yoo, Jeong-Ju and Lee, Sae Hwan and Kim, Sang Gyune and Kim, Young Seok and Kim, Hong Soo and Kim, Seung Up and Jang, Jae Young},
  title = {Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C},
  journal = {Clinical and Molecular Hepatology},
  year = {2025},
  doi = {10.3350/cmh.2024.0904}
}
Kostenlos starten →